Patients with Moderate-to-Severe SLE are Increasingly Being
In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed....
Source: globenewswire.com
Page 5 - Spherix Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Spherix Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Spherix Network Today - Breaking & Trending Today
Don't Mess with Success: U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights
/PRNewswire/ -- Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global...
Source: prnewswire.com
The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
/PRNewswire/ -- The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S....
Source: prnewswire.com
Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights
/PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis...
Source: prnewswire.com
New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights
/PRNewswire/ -- According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus...
Source: prnewswire.com